(MENAFN- EIN Presswire)
Diabetes Pipeline
Diabetes Pipeline
LAS VEGAS, NV, UNITED STATES, January 20, 2025 /EINPresswire / -- DelveInsight's,“Diabetes Pipeline Insights” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Diabetes Pipeline. Dive into DelveInsight's comprehensive report today! @ Diabetes Pipeline Outlook
Key takeaways from the Diabetes Pipeline Report
.In January 2025:- The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India. The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).
.DelveInsight's Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
.The leading Diabetes Companies such as Daewoong Tradipitant, Janssen Biotech,Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
.Promising Diabetes Therapies such as Aspirin, DA-2811, Forxiga, TG103, and others.
Stay ahead with the most recent pipeline outlook for Diabetes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs
Diabetes Emerging Drugs Profile
.Enavogliflozin - Daewoong
Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.
.Golimumab - Janssen Biotech
Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNFα. It inhibits soluble and transmembrane forms of TNF-α by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.
Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline. Access DelveInsight's detailed report now! @ New Diabetes Drugs
Diabetes Companies
Daewoong Tradipitant, Janssen Biotech,Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
.Oral
.Parenteral
.intravitreal
.Subretinal
.Topical.
.Molecule Type
Diabetes Products have been categorized under various Molecule types such as
.Monoclonal Antibody
.Peptides
.Polymer
.Small molecule
.Gene therapy
.Product Type
Unveil the future of Diabetes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Diabetes Market Drivers and Barriers-
Scope of the Diabetes Pipeline Report
.Coverage- Global
.Diabetes Companies- Daewoong Tradipitant, Janssen Biotech,Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
.Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and others.
.Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
.Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Diabetes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs-
Table of Introduction
2 of and by Product by Stage and Product by Route of by Stage and Route of by Molecule by Stage and Molecule – DelveInsight's Analytical Commercial companies' collaborations, Licensing, Acquisition -Deal Value Collaboration Collaborations (Licensing / Partnering) Collaborations (Licensing / Partnering) Stage Products (Phase and Development Stage Products (Phase Janssen and Development profiles in the detailed Stage Products (Phase and Development profiles in the detailed and Discovery Stage and Development profiles in the detailed Key Key Unmet Market Drivers and Future Perspectives and Analyst Key
List of Top Selling Market Research Reports in 2025
Varicose Vein Treatment Devices Market -
Vascular Access Devices Market -
Indwelling Catheters Market -
Healthcare Competitive Benchmarking -
Lymphoedema Market -
Pacemakers Market -
Myeloproliferative Neoplasms Market -
Surgical Mask & Respirator Market -
Nk Cell Therapy Market -
Novel Drug Delivery Devices Market -
Testicular Neoplasm Market -
Phototherapies For Psoriasis Market -
Skin Neoplasm Market -
Microscopy Device Market -
Bone Growth Stimulator Market -
Urea Cycle Disorders Market -
Antibody Drug Conjugate Market -
Penile Cancer Market -
Total Knee Arthroplasty Market -
Cardiac Implantable Electronic Devices Market -
Dyspepsia Market -
Lactose Intolerance Market -
Medical Marijuana Market -
Asperger Syndrome Market -
Catheter Stabilization Devices Market -
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Yash Bhardwaj
DelveInsight
+91 9650213330
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN20012025003118003196ID1109108470
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.